DOXAPRAM AND THE NEUROMUSCULAR JUNCTION
We have studied the action of doxapram on neuromuscular transmission in the rat phrenic nerve—diaphragm preparation. Doxapram augmented neuromuscular transmission in a doserelated manner when a threshold concentration of 5 × 10−5 mol litre−1 had been exceeded. The activity of the acetylcholinesteras...
Gespeichert in:
Veröffentlicht in: | British journal of anaesthesia : BJA 1989-06, Vol.62 (6), p.664-668 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We have studied the action of doxapram on neuromuscular transmission in the rat phrenic nerve—diaphragm preparation. Doxapram augmented neuromuscular transmission in a doserelated manner when a threshold concentration of 5 × 10−5 mol litre−1 had been exceeded. The activity of the acetylcholinesterase in rat diaphragm has been examined also in the presence of doxapram. No inhibitory effect was seen in the concentration range which augmented neuromuscular transmission, thus excluding cholinesterase inhibition as the underlying mechanism. In contrast, in the presence of partial neuromuscular block, a dose-related depression of neuromuscular transmission with doxapram was revealed. This was greatest when the neuromuscular blocking agents possessed significant presynaptic activity (β-bungarotoxin and tubocurarine). In this situation any facilitatory action of doxapram was severely reduced or abolished. In contrast, the facilitatory effects of doxapram were apparent in the presence of partial block produced by agents with less or no presynaptic activity (pancuronium and α-bungarotoxin). This study suggests that doxapram has a presynaptic facilitatory action at the neuromuscular junction. In the presence of partial neuromuscular block, an inhibitory action is revealed which may be post-junctional. The concentrations of doxapram at which these effects appear are approximately five times greater than those reached in plasma after a standard clinical dose. |
---|---|
ISSN: | 0007-0912 1471-6771 |
DOI: | 10.1093/bja/62.6.664 |